MyFinsight
Home
Blog
About
Contact
Download
Download image
Issuance of commons
shares (note 10)
$42,436K
Proceeds from the
exercise of stock options...
$8K
Net cash provided by
financing activities
$41,138K
Canceled cashflow
$1,306K
Net increase in cash
and cash...
$2,689K
Canceled cashflow
$38,449K
Payments of financing
costs (note 10)
$1,016K
Repayments of long-term
debt (note 8)
$290K
Share-based compensation
(note 11)
$5,490K
Prepaid expenses and
deposits
-$464K
Accounts payable,
accrued expenses and...
$378K
Depreciation of property and
equipment (note 5)
$373K
Deferred revenue
$371K
Amortization of intangible
assets (note 6)
$187K
Interest and accretion
expense (note 8)
$63K
Income taxes payable
(note 13)
$42K
Deferred tax assets (note
13)
-$26K
Net cash used in
operating activities
-$38,207K
Net cash used in
investing activities
-$242K
Canceled cashflow
$7,394K
Net loss for the year
-$42,570K
Purchase of property and
equipment (note 5)
$176K
Purchase of intangible
assets (note 6)
$66K
Inventory (note 4)
$2,822K
Trade and other
receivables (note 3)
$172K
Non-cash lease expense
adjustment
$37K
Back
Back
Cash Flow
source: myfinsight.com
Profound Medical Corp. (PROF)
Profound Medical Corp. (PROF)